- Navidea Biopharmaceuticals (NAVB -6.7%) slides after saying the EMA "has provided updated Day 180 feedback and has elected to continue the assessment of the" Lymphoseek MAA.
- The company notes that there was "less time for evaluation ... of new data" as Phase 3 Head and Neck Cancer results were submitted "later in the MAA review process at Day 120."
- Here's CEO Mark Pykett: "With the Lymphoseek MAA remaining in the EMA's assessment process, we will continue to work with the EMA to support a positive opinion as early as possible in 2014."
- NAVB says it still sees its plans for European market development supporting "material revenue generation from Europe beginning in 2015." (PR)
Navidea Biopharmaceuticals talks MAA for Lymphoseek, shares slide
Dec 20 2013, 13:14 ET